The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.

Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.

Treatment with interferon beta-1b in combination with lopinavir/ritonavir and ribavirin was found to be safe and superior to lopinavir/ritonavir alone for reducing the duration of viral shedding and hospital stay in adults with COVID-19.